Palatin Technologies, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended March 31, 2024; filed May 15, 2024. The filing covers fiscal 2024 Q3, not 2023 Q3.
Business context
Palatin is a clinical-stage biopharmaceutical company developing melanocortin-based therapies, with current development focused mainly on MC1r programs for inflammatory and autoimmune conditions, including ocular diseases. Cosette acquired worldwide rights to Palatin’s former commercial product, Vyleesi, on December 19, 2023. Palatin therefore reports no product revenue for the quarter and says it no longer has a recurring revenue source.
Key financial results
| Metric | Three months ended March 31, 2024 | Nine months ended March 31, 2024 | Comparable 2023 period |
|---|---|---|---|
| Net product revenue | $0 | $4.14 million | $1.20 million and $3.09 million, respectively |
| Research and development expense | $7.16 million | $17.73 million | $4.83 million and $15.22 million, respectively |
| Selling, general and administrative expense | $2.03 million | $8.27 million | $3.54 million and $10.22 million, respectively |
| Net loss | $8.44 million | $21.49 million | $8.67 million and $14.22 million, respectively |
| Basic and diluted loss per share | $0.53 | $1.53 | $0.76 and $1.34, respectively |
The nine-month 2024 results include a $7.80 million gain on the Vyleesi sale and a $6.96 million noncash expense from changes in warrant fair value. The comparable 2023 nine-month period included a $4.67 million income tax benefit from selling New Jersey tax attributes. The filing does not provide a meaningful operating margin comparison given the transition away from Vyleesi sales.
Cash, liquidity and obligations
- Cash and cash equivalents were $10.01 million at March 31, 2024, versus $7.99 million at June 30, 2023. Total current assets were $10.27 million; current liabilities were $8.53 million.
- Operating activities used $24.99 million of cash in the nine months, compared with $19.67 million in the prior-year period. Investing activities provided $12.46 million, primarily from the $9.50 million Vyleesi sale proceeds and maturity of marketable securities. Financing activities provided $14.56 million, primarily from equity offerings.
- Management says existing cash is expected to fund planned operations into the second half of calendar 2024. It nevertheless concluded that substantial doubt exists about the company’s ability to continue as a going concern for one year after issuance of the financial statements.
- The filing discloses no material conventional borrowing balance. Lease liabilities totaled approximately $707,000; inventory purchase commitments were $3.92 million, with $3.31 million accrued as estimated losses in current and long-term liabilities.
Material changes, outlook and risks
- Vyleesi transaction: Cosette paid $9.50 million upfront; the agreement provides for up to $2.50 million upon settlement of certain purchase commitments and up to $159 million in sales-based milestones. Palatin has no control over Cosette’s sales efforts and may receive little or no milestone revenue. Separate retained regulatory milestones include $7.50 million tied to approval in China and $3.00 million tied to first commercial sale in Korea.
- Development spending: R&D expense rose year over year, which management attributed primarily to increased spending on melanocortin receptor programs. The filing identifies PL9643 for dry eye disease, PL8177 for ulcerative colitis, and a diabetic-nephropathy proof-of-concept program. It references top-line Phase 3 results for PL9643 announced in February 2024 but does not provide the results in the supplied filing text.
- Funding and dilution: The company is evaluating equity financing, debt, expense reductions, or strategic alternatives. October 2023 and January 2024 offerings generated net proceeds, but further financing is not assured. Common shares outstanding increased to 16.14 million from 11.66 million at June 30, 2023; outstanding warrants, options, preferred shares and restricted stock units create additional potential dilution.
- Controls: Management concluded disclosure controls were ineffective because of a material weakness in accounting for complex financial instruments, including warrants. The company revised prior-period amounts for warrant classification and fair-value accounting, while stating the prior-period effects were not material.
- Listing and supply risks: Palatin was not in compliance with NYSE American stockholders’ equity standards; the exchange accepted a compliance plan, with a stated deadline of April 10, 2025, but reinstatement is not assured. The filing also flags potential Vyleesi supply disruption related to Catalent’s announced transaction and planned sale of its Brussels facility.
No formal financial guidance is provided. Management expects continued losses and says additional funding is needed to complete clinical development. Failure to obtain funding could force program reductions, asset sales, a strategic transaction or cessation of operations.
Most important facts for investors to verify
- Current cash runway, cash burn and the timing, amount and terms of any additional financing.
- PL9643 Phase 3 top-line results and the next clinical milestones for PL9643, PL8177 and other programs.
- Cosette’s Vyleesi sales progress, milestone thresholds and any payments received under the purchase agreement.
- Progress in remediating the warrant-accounting material weakness and any further revisions to reported financials.
- NYSE American compliance-plan milestones and the potential impact of dilution from outstanding securities.